Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dickon Hayne

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Nature Reviews. Urology|March 9, 2016
Enhancing active surveillance of prostate cancer: the potential of exercise medicineDaniel A Galvão, Dennis R Taaffe, Nigel Spry, et al.
European Urology Oncology|October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
BMC Cancer|February 13, 2025
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocolEric Wegener, Michael Ng, Mario Guerrieri, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
Journal of Patient-Reported Outcomes|March 27, 2025
Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SIClaudia Rutherford, Margaret-Ann Tait, Daniel S J Costa, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Urology|February 3, 2026
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Dickon Hayne, Alison Y Zhang, Hayley Thomas, et al.
The Journal of Urology|October 9, 2024
Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center CohortYair Lotan, Viswesh Krishna, Waleed M Abuzeid, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Nature Reviews. Urology|March 9, 2016
Enhancing active surveillance of prostate cancer: the potential of exercise medicineDaniel A Galvão, Dennis R Taaffe, Nigel Spry, et al.
European Urology Oncology|October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
BMC Cancer|February 13, 2025
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocolEric Wegener, Michael Ng, Mario Guerrieri, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
Journal of Patient-Reported Outcomes|March 27, 2025
Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SIClaudia Rutherford, Margaret-Ann Tait, Daniel S J Costa, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Urology|February 3, 2026
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Dickon Hayne, Alison Y Zhang, Hayley Thomas, et al.
The Journal of Urology|October 9, 2024
Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center CohortYair Lotan, Viswesh Krishna, Waleed M Abuzeid, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 8